Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PEPMIDAS

Financiado

Cerrado

Gold III based anticancer agents dithiocarbamato peptide derivatives as improv...

Gold III based anticancer agents dithiocarbamato peptide derivatives as improved intracellular drug transfer and delivery systems supported by transporter proteins The ultimate objective of this research work is the preparation and evaluation of novel gold(III)-di/tripeptidedithiocarbamato complexes for combating cancer through their enhanced selective delivery at the tumor target site suppo... ver más

31/12/2010

UNIPD

45K€

Presupuesto del proyecto: 45K€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PADOVA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2010-12-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIPD

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TSPO METALLODRUGS Novel highly effective and selective anticancer metallodrug... 176K€ Cerrado

RYC-2011-07787 New photoactive metal complexes as dual anticancer drugs 184K€ Cerrado

SMARTDRUGENTITIES Sophisticated Well Targeted Therapeutic Entities based on Bi... 1M€ Cerrado

RUPROLIGHT Light activatable ruthenium based anticancer prodrugs 1M€ Cerrado

TiDrugArchitectures Highly Competent and Safe Titanium IV Therapeutic Framework... 2M€ Cerrado

PhoRAu Photochemistry and radiolabelling of gold III anticancer pr... 158K€ Cerrado

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PADOVA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 45K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The ultimate objective of this research work is the preparation and evaluation of novel gold(III)-di/tripeptidedithiocarbamato complexes for combating cancer through their enhanced selective delivery at the tumor target site supported by transporter proteins. Platinum(II) drugs are now established as effective antitumour agents, the archetypal example of these being cisplatin. However, their usefulness is limited by their narrow spectrum of activity (not active enough against several types of cancer), and by both the development of acquired resistance after continuous treatment and toxicity (in particular, nephrotoxicity). Thus, several third-generation metal-based drugs have been prepared and tested. In this contest, gold(III) compounds are emerging as a new class of metal complexes with outstanding cytotoxic properties, and are presently being evaluated as potential antitumor agents. In particular, some gold(III)-dithiocarbamato derivatives were proved to be much more cytotoxic in vitro than cisplatin, and showed encouraging results in terms of both high in vivo effectiveness and lack of nephrotoxicity. This research project is concerned with the synthesis and characterization of new gold(III)-dithiocarbamato derivatives of di/tripeptides as improved peptide-based delivery systems, to be evaluated as antitumor drugs. The rationale behind our proposal is to design gold(III) complexes of the type [AuX2(pdtc)] (X = Cl, Br; pdtc = di/tripeptidedithiocarbamate) which can be able to both maintain the antitumor properties and the lack of nephrotoxicity of the previously reported gold(III) analogues, together with an enhanced bioavailability through the di/tripeptide-mediated cellular internalization promoted by transporter proteins. Thus, the enormous potential impact of this new class of gold(III) chemotherapeutic agents relies in their possible site-specific delivery in localized cancers strongly improving their cellular uptake and minimizing unwanted side-effects.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores